Sawada Y, Kawai R, McManaway M, Otsuki H, Rice K C, Patlak C S, Blasberg R G
Nuclear Medicine Department Clinical Center, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892.
J Cereb Blood Flow Metab. 1991 Mar;11(2):183-203. doi: 10.1038/jcbfm.1991.51.
[3H]Cyclofoxy (CF: 17-cyclopropylmethyl-3,14-dihydroxy-4,5-alpha-epoxy-6-beta-fluoromorp hinan) is an opioid antagonist with affinity to both mu and kappa subtypes that was synthesized for quantitative evaluation of opioid receptor binding in vivo. Two sets of experiments in rats were analyzed. The first involved determining the metabolite-corrected blood concentration and tissue distribution of CF in brain 1 to 60 min after i.v. bolus injection. The second involved measuring brain washout for 15 to 120 s following intracarotid artery injection of CF. A physiologically based model (Sawada et al., 1990a) and a classical compartmental pharmacokinetic model (Wong et al., 1986a) were compared. The models included different assumptions for transport across the blood-brain barrier (BBB); estimates of nonspecific tissue binding and specific binding to a single opiate receptor site were found to be essentially the same with both models. The nonspecific binding equilibrium constant varied modestly in different brain structures (Keq = 3-9), whereas the binding potential (BP) varied over a much broader range (BP = 0.6-32). In vivo estimates of the opioid receptor dissociation constant were similar for different brain structures (KD = 2.1-5.2 nM), whereas the apparent receptor density (Bmax) varied between 1 (cerebellum) and 78 (thalamus) pmol/g of brain. The receptor dissociation rate constants in cerebrum (k4 = 0.08-0.16 min-1; koff = 0.16-0.23 min-1) and brain vascular permeability (PS = 1.3-3.4 ml/min/g) are sufficiently high to achieve equilibrium conditions within a reasonable period of time. Graphical analysis (Patlak and Blasberg, 1985) of the data is inappropriate due to the high tissue-loss rate constant (kb = 0.03-0.07 min-1) for CF in brain. From these findings, CF should be a very useful opioid receptor ligand for the estimation of the receptor binding parameters in human subjects using [18F]CF and positron emission tomography.
[3H]环福可昔(CF:17-环丙基甲基-3,14-二羟基-4,5-α-环氧-6-β-氟吗啡喃)是一种对μ和κ亚型均有亲和力的阿片类拮抗剂,其合成目的是用于体内阿片受体结合的定量评估。分析了在大鼠身上进行的两组实验。第一组实验涉及在静脉推注后1至60分钟测定CF在脑中经代谢物校正后的血药浓度和组织分布。第二组实验涉及在颈内动脉注射CF后15至120秒测量脑内清除情况。比较了一个基于生理学的模型(泽田等人,1990a)和一个经典的房室药代动力学模型(黄等人,1986a)。这些模型对跨血脑屏障(BBB)转运包含不同假设;发现两种模型对非特异性组织结合和与单一阿片受体位点的特异性结合的估计基本相同。非特异性结合平衡常数在不同脑结构中变化不大(Keq = 3 - 9),而结合势(BP)的变化范围则大得多(BP = 0.6 - 32)。不同脑结构的阿片受体解离常数的体内估计值相似(KD = 2.1 - 5.2 nM),而表观受体密度(Bmax)在每克脑1(小脑)至78(丘脑)皮摩尔之间变化。大脑中的受体解离速率常数(k4 = 0.08 - 0.16分钟-1;koff = 0.16 - 0.23分钟-1)和脑血管通透性(PS = 1.3 - 3.4毫升/分钟/克)足够高,能够在合理时间内达到平衡状态。由于CF在脑中的组织损失速率常数较高(kb = 0.03 - 0.07分钟-1),对数据进行图形分析(帕特拉克和布拉斯伯格,1985)并不合适。基于这些发现,CF应该是一种非常有用的阿片受体配体,可用于使用[18F]CF和正电子发射断层扫描来估计人类受试者的受体结合参数。